Beacon Investment Advisory Services Inc. Sells 9,055 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Beacon Investment Advisory Services cut its Regeneron position by 92.3%, selling 9,055 shares and retaining 757 shares valued at approximately $472,000. Institutional investors own 83.31% of the company.
• Regeneron reported a strong quarterly performance, with adjusted earnings of $14.29 per share and revenue of $4.29 billion, surpassing analyst estimates; revenue increased 16.7% year over year.
• Analysts maintain a generally positive outlook, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $797.75. Regeneron also declared a quarterly dividend of $0.94 per share, while pending securities litigation represents a key risk.

Beacon Investment Advisory Services Inc. lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 92.3% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 757 shares of the biopharmaceutical company's stock after selling 9,055 shares during the period. Beacon Investment Advisory Services Inc.'s holdings in Regeneron Pharmaceuticals were worth $472,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. WPG Advisers LLC lifted its position in Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 25 shares during the last quarter. SHP Wealth Management purchased a new position in Regeneron Pharmaceuticals in the fourth quarter worth $26,000. Western Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter worth $26,000. Titan Wealth CI Ltd acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth $29,000. Finally, Kemnay Advisory Services Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $31,000. Institutional investors own 83.31% of the company's stock.

Insider Buying and Selling

In other news, Director Arthur F. Ryan sold 200 shares of the company's stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the sale, the director directly owned 17,303 shares of the company's stock, valued at $11,249,545.45. This represents a 1.14% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.97% of the company's stock.

Regeneron Pharmaceuticals Stock Up 1.6%

Regeneron Pharmaceuticals stock opened at $784.36 on Friday. The business's 50-day simple moving average is $657.28 and its two-hundred day simple moving average is $712.33. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. The company has a market cap of $82.92 billion, a PE ratio of 19.39, a PEG ratio of 1.34 and a beta of 0.22. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $541.00 and a fifty-two week high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping analysts' consensus estimates of $10.16 by $4.13. The firm had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The company's revenue was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $12.81 earnings per share. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be paid a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date is Tuesday, August 18th. Regeneron Pharmaceuticals's payout ratio is presently 9.29%.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on REGN. Sanford C. Bernstein raised Regeneron Pharmaceuticals to a "hold" rating in a research report on Wednesday, July 29th. Wells Fargo & Company increased their price target on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an "equal weight" rating in a research note on Friday, July 31st. Citigroup raised their price target on Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the stock a "neutral" rating in a report on Monday, August 3rd. BMO Capital Markets dropped their price target on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an "outperform" rating on the stock in a research note on Monday, May 18th. Finally, Morgan Stanley upped their price objective on shares of Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the company an "equal weight" rating in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $797.75.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Barclays maintained its Buy rating on Regeneron. The reaffirmed bullish view provides support for REGN, particularly after the company’s recent earnings beat, which included revenue growth and earnings per share well above consensus. Barclays Keeps Their Buy Rating on Regeneron
• Neutral Sentiment: Intellia Therapeutics reported lower revenue because of reduced Regeneron collaboration revenue. Intellia’s second-quarter revenue declined 46.2%, but the item reflects Intellia’s financial results rather than a newly announced change in Regeneron’s pipeline or partnership strategy. NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues
• Negative Sentiment: Several law firms reiterated notices about a pending securities class action against Regeneron. The lawsuit concerns alleged disclosure issues surrounding the failed Phase 3 melanoma trial, which reportedly led to a substantial market-value loss. Investors who purchased REGN shares during the August 1, 2025–May 15, 2026 class period have until September 14, 2026 to seek lead-plaintiff status. The repeated notices add legal and reputational risk but do not indicate a new lawsuit-related financial liability. Regeneron Class Action Lawsuit Deadline Notice

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source